MA39809A - Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih - Google Patents

Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih

Info

Publication number
MA39809A
MA39809A MA039809A MA39809A MA39809A MA 39809 A MA39809 A MA 39809A MA 039809 A MA039809 A MA 039809A MA 39809 A MA39809 A MA 39809A MA 39809 A MA39809 A MA 39809A
Authority
MA
Morocco
Prior art keywords
reverse transcriptase
transcriptase inhibitors
hiv reverse
substituted nucleoside
nucleoside derivatives
Prior art date
Application number
MA039809A
Other languages
English (en)
Other versions
MA39809B1 (fr
Inventor
Jianmin Fu
Vinay M Girijavallabhan
David B Olsen
Bing-Yu Tang
Zhibo Zhang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA39809A publication Critical patent/MA39809A/fr
Publication of MA39809B1 publication Critical patent/MA39809B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA39809A 2014-03-28 2015-03-26 Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih MA39809B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (fr) 2014-03-28 2014-03-28 Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse
PCT/US2015/022621 WO2015148746A1 (fr) 2014-03-28 2015-03-26 Dérivés nucléosidiques 4'-substitués utilisés comme inhibiteurs de la transcriptase inverse du vih

Publications (2)

Publication Number Publication Date
MA39809A true MA39809A (fr) 2021-04-07
MA39809B1 MA39809B1 (fr) 2021-10-29

Family

ID=52824598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39809A MA39809B1 (fr) 2014-03-28 2015-03-26 Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih

Country Status (42)

Country Link
US (2) US9777035B2 (fr)
EP (1) EP3122752B1 (fr)
JP (1) JP6182680B2 (fr)
KR (1) KR101961009B1 (fr)
CN (1) CN106795199B (fr)
AP (1) AP2016009482A0 (fr)
AR (2) AR099788A1 (fr)
AU (2) AU2015236018B2 (fr)
CA (1) CA2943792C (fr)
CL (1) CL2016002414A1 (fr)
CR (1) CR20160451A (fr)
CY (1) CY1124829T1 (fr)
DK (1) DK3122752T3 (fr)
DO (1) DOP2016000265A (fr)
EA (1) EA031476B1 (fr)
EC (1) ECSP16085206A (fr)
ES (1) ES2894228T3 (fr)
GE (2) GEAP201914307A (fr)
GT (1) GT201600201A (fr)
HR (1) HRP20211622T1 (fr)
HU (1) HUE056913T2 (fr)
IL (1) IL247923B (fr)
JO (1) JO3636B1 (fr)
LT (1) LT3122752T (fr)
MA (1) MA39809B1 (fr)
MD (1) MD4812C1 (fr)
MX (1) MX367058B (fr)
MY (1) MY194635A (fr)
NI (1) NI201600145A (fr)
NZ (1) NZ724343A (fr)
PE (1) PE20170197A1 (fr)
PH (1) PH12016501897B1 (fr)
PL (1) PL3122752T3 (fr)
PT (1) PT3122752T (fr)
RS (1) RS62418B1 (fr)
SG (1) SG11201608031PA (fr)
SI (1) SI3122752T1 (fr)
SV (1) SV2016005290A (fr)
TW (1) TWI660967B (fr)
UA (1) UA120758C2 (fr)
WO (2) WO2015143712A1 (fr)
ZA (1) ZA201606413B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA42608A (fr) 2015-08-13 2018-06-20 Merck Sharp & Dohme Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
KR102185996B1 (ko) * 2015-09-23 2020-12-02 머크 샤프 앤드 돔 코포레이션 4'-치환된 뉴클레오시드 리버스 트랜스크립타제 억제제 및 그의 제조법
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2017223414A1 (fr) 2016-06-24 2017-12-28 Incyte Corporation Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y
RS62410B1 (sr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]tiofenska jedinjenja kao agonisti sting
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2019027857A1 (fr) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b]thiophéniques pour le traitement du cancer
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
US11149049B2 (en) * 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2019125974A1 (fr) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Composés dinucléotidiques cycliques utilisés comme agonistes sting
MX2020006864A (es) * 2017-12-27 2020-11-11 Univ Emory Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ療法に有用な化合物
WO2019195124A1 (fr) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
WO2019195063A1 (fr) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting
MX2021000278A (es) 2018-07-09 2021-03-31 Merck Sharp & Dohme Llc Sintesis enzimatica de analogos de nucleosido de 4'-etinilo.
US20220117993A1 (en) * 2018-08-09 2022-04-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
EP3914604B1 (fr) 2019-01-25 2026-03-04 Brown University Compositions comprenant du censavudine ou de l'elvucitabine pour le traitement de l'inflammation et des troubles associés à l'âge
EA202192433A1 (ru) * 2019-03-06 2021-12-28 Глэксосмитклайн Интеллекчуал Проперти (№2) Лимитед Соединения, полезные в терапии вич
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法
BR112022000965A2 (pt) * 2019-07-27 2022-06-14 Brii Biosciences Inc Derivado de adenosina e composição farmacêutica que compreende o mesmo
EP4028020A4 (fr) * 2019-09-11 2023-09-27 The Scripps Research Institute Promédicaments antiviraux et formulations de ceux-ci
CN114786648A (zh) * 2019-12-09 2022-07-22 Viiv保健公司 包含卡博特韦的药物组合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (fr) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Composés antiviraux
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
EP4172160A2 (fr) 2020-06-24 2023-05-03 Gilead Sciences, Inc. Analogues de 1'-cyano nucléoside et leurs utilisations
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
HUE067491T2 (hu) * 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
CN116801884B (zh) 2021-01-25 2026-02-27 腾盛博药生物科技有限公司 使用腺苷衍生物和衣壳抑制剂的针对hiv的组合疗法
CA3202049A1 (fr) * 2021-01-25 2022-07-28 Brii Biosciences, Inc. Derive d'adenosine et composition pharmaceutique le comprenant
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
EP4387977A1 (fr) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Composés phospholipidiques et leurs procédés de production et d'utilisation
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
WO2023046900A1 (fr) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Analogues de ribonucléosides dirigés contre le sars-cov-2
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
JP2025509635A (ja) 2022-03-15 2025-04-11 ローム・セラピューティクス・インコーポレイテッド 疾患を治療するための化合物及び方法
EP4547665A1 (fr) * 2022-06-30 2025-05-07 Gilead Sciences, Inc. Formes solides d'un analogue nucléosidique et leurs utilisations
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
KR20250140092A (ko) 2023-01-30 2025-09-24 머크 샤프 앤드 돔 엘엘씨 4'-치환된 뉴클레오시드 리버스 트랜스크립타제 억제제의 전구약물
EP4704831A2 (fr) * 2023-04-26 2026-03-11 Lakewood Amedex, Inc. Composés de pyrimidinone et d'azapyrimidinone substitués, compositions et utilisations associées
US20250026759A1 (en) 2023-07-07 2025-01-23 Merck Sharp & Dohme Llc Tetrahydroquinazoline derivatives as selective cytotoxic agents

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651569B2 (en) 1990-01-11 1994-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating RNA activity and gene expression
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
HUP0001186A3 (en) 1996-10-16 2002-04-29 Icn Pharmaceuticals Inc Costa Purine l-nucleosides,analogs and pharmaceutical compositions thereof
DE60005501T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-pyrimidine nukleoside
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2003062256A1 (fr) 2002-01-17 2003-07-31 Ribapharm Inc. Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
WO2003099840A1 (fr) 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides a unites nucleosidiques modifiees
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
WO2005003047A1 (fr) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Vitre pouvant etre chauffee par une lumiere invisible
CA2502109C (fr) 2004-03-24 2010-02-23 Yamasa Corporation Derive de 2-haloadenosine avec substitution sur le carbone en position 4'
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CN101003550B (zh) * 2006-12-30 2010-05-19 河南省分析测试研究中心 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
AU2009240630B2 (en) 2008-04-23 2013-07-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (fr) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Analogues nucléosidiques antiviraux
EP2313102A2 (fr) 2008-07-03 2011-04-27 Biota Scientific Management Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
CN102216316A (zh) 2008-09-05 2011-10-12 寿制药株式会社 取代胺衍生物及以其为有效成分的药物组合物
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (fr) 2008-12-23 2018-07-03 Pharmasset, Inc. Phosphoramidates de nucleosides
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
MX2011009728A (es) 2009-03-20 2011-10-14 Alios Biopharma Inc Analogos nucleotido y nucleosido sustituidos.
WO2011005860A2 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Mimétiques de 5' phosphate
MA33926B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
KR20130083389A (ko) 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
AU2013232378B2 (en) * 2012-03-13 2017-09-28 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
MD4812B1 (ro) 2022-06-30
DOP2016000265A (es) 2017-04-30
BR112016022438A8 (pt) 2021-06-29
CA2943792A1 (fr) 2015-10-01
AU2015236018B2 (en) 2017-09-28
WO2015148746A1 (fr) 2015-10-01
SI3122752T1 (sl) 2021-11-30
BR112016022438A2 (pt) 2017-08-15
AU2017225090A1 (en) 2017-09-28
CA2943792C (fr) 2020-02-25
RS62418B1 (sr) 2021-10-29
SV2016005290A (es) 2018-05-03
NZ724343A (en) 2020-02-28
EP3122752B1 (fr) 2021-08-25
AR130699A2 (es) 2025-01-08
MX2016012659A (es) 2016-12-14
CN106795199B (zh) 2020-01-10
MD4812C1 (ro) 2023-01-31
GEAP201914307A (en) 2019-04-10
MA39809B1 (fr) 2021-10-29
PE20170197A1 (es) 2017-03-22
GT201600201A (es) 2018-12-18
TWI660967B (zh) 2019-06-01
WO2015143712A1 (fr) 2015-10-01
NI201600145A (es) 2016-10-27
PL3122752T3 (pl) 2022-01-03
DK3122752T3 (da) 2021-10-25
EA031476B1 (ru) 2019-01-31
ECSP16085206A (es) 2017-08-31
CL2016002414A1 (es) 2017-05-05
TW201619180A (zh) 2016-06-01
US9777035B2 (en) 2017-10-03
CN106795199A (zh) 2017-05-31
SG11201608031PA (en) 2016-10-28
HUE056913T2 (hu) 2022-03-28
MY194635A (en) 2022-12-08
AU2017225090B2 (en) 2018-08-09
PT3122752T (pt) 2021-10-20
ES2894228T3 (es) 2022-02-14
EA201691931A1 (ru) 2017-02-28
EP3122752A1 (fr) 2017-02-01
MD20160117A2 (ro) 2017-02-28
IL247923B (en) 2021-01-31
AP2016009482A0 (en) 2016-10-31
AR099788A1 (es) 2016-08-17
GEP20197009B (en) 2019-08-12
CR20160451A (es) 2016-12-06
JP2017512797A (ja) 2017-05-25
MX367058B (es) 2019-08-02
JO3636B1 (ar) 2020-08-27
KR20160128437A (ko) 2016-11-07
KR101961009B1 (ko) 2019-03-21
CY1124829T1 (el) 2022-11-25
HRP20211622T1 (hr) 2022-03-04
US20150274767A1 (en) 2015-10-01
PH12016501897A1 (en) 2016-12-19
PH12016501897B1 (en) 2023-08-02
AU2015236018A1 (en) 2016-10-06
JP6182680B2 (ja) 2017-08-16
US20180002366A1 (en) 2018-01-04
LT3122752T (lt) 2021-11-10
UA120758C2 (uk) 2020-02-10
ZA201606413B (en) 2018-04-25
IL247923A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MA39809A (fr) Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih
HUE056634T2 (hu) Rákellenes szerekként hasznos szubsztituált karbonukleozid-származékok
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3319956T3 (da) Substituerede oxopyridinderivater
HUE041926T2 (hu) IRAK4 inhibitor biciklusos heterociklilszármazékok
MA45646A (fr) Derives de benzimidazole comme des modulateurs de ror-gamma
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
DK3389379T3 (da) Mikrobiocide phenylamidinderivater
LT3402792T (lt) Chinolin-2-ono dariniai
PT3457851T (pt) Derivados de sobetiroma
HUE055463T2 (hu) Eljárás glükopiranozil-szubsztituált benzil-benzol-származékok elõállítására
EP3443043A4 (fr) Compositions de prétraitement
FR3023290B1 (fr) Derives de flavaglines
PT3131898T (pt) Derivados de fluoroalquilfluoreno
HUE054815T2 (hu) 3,5-Difenil-diazol vegyületek vízoldható származékai
SMT202200201T1 (it) Derivati di tetraidroisochinolina
EP3532269A4 (fr) Compositions de prétraitement
HRP20182016T1 (hr) Derivati etinila
BR112016027819A2 (pt) Processo de preparação de derivados de tiazole